Hsp90 as Potential Treatment for Lung Cancer

Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University, discusses the role of heat shock protein 90 (Hsp90) in the treatment of lung cancer.

Clinical Pearls:

• Hsp90 is a rational targeted for cancer since a number of oncoproteins depend on the associate of Hsp90 in order to become active.
• The drug ganetespib has now been combined with chemotherapy in randomized trials as a potential treatment option for lung cancer.
• GALAXY-2, a phase III trial, will randomize patients to docetaxel with or without ganetespib.